Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279654 · ClinicalTrials.gov registry record
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 389
- Enrollment target
NCT02279654 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 389 participants.
The verdict
NCT02279654 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 389 participants
- Enrollment target
Study Summary
This registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with Transfusion Dependent, IPSS low or intermediate-1-Risk Myelodysplastic Syndrome (MDS), associated to a single abnormality of the chromosome 5 \[del(5q)\]. The purpose of this study is to collect additional data about the safety of an oral drug (lenalidomide, Revlimid®) that may have been prescribed to relieve anemia and decrease the need of blood transfusions. However, also patients affected by the MDS del(5q) who receive other treatments different from lenalidomide can be included in this study, if they agree.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2022-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279654
The ClinicalTrials.gov registry entry for NCT02279654 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT02279654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02279654 about?
NCT02279654 is a clinical study titled "Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)". This registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with Transfusion Dependent, IPSS low or intermediate-1-Risk Myelodysplastic Syndrome (MDS), associated to a single abnormality of the chromosome 5 \[del(5q)\]. The purpose of this study is to ...
What is the current status of trial NCT02279654?
This trial is currently completed. The enrollment target is 389 participants. The study started on 2014-12-17. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT02279654?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02279654?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.